Recurrent Abdominal Pain in Children

Sponsor
Baylor College of Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT00526903
Collaborator
National Institute of Nursing Research (NINR) (NIH)
168
1
2
61.9
2.7

Study Details

Study Description

Brief Summary

The purpose of this study is to:
  1. To determine if fiber versus placebo improves symptoms in children with recurrent abdominal pain/irritable bowel syndrome.

  2. To determine possible ways fiber or placebo improve(s) symptoms in children with recurrent abdominal pain/irritable bowel syndrome by carrying out gastrointestinal tests and questionnaires.

Understanding how diet and fiber affect GI function potentially will benefit the large numbers of children with irritable bowel syndrome (IBS) and provide insight into prevention of IBS in at risk children. We expect that the results from these studies can be used to lessen significantly the huge financial burden to society caused by these chronic conditions.

Consent will be obtained from the parent/guardian and assent from the child.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Elimination Diet
Phase 2

Detailed Description

Children with recurrent abdominal pain (RAP) who meet the criteria for irritable bowel syndrome (IBS) will be recruited and studied. They will have been diagnosed by a pediatric gastroenterologist and will have had at least one healthcare visits in the past year for the complaint of abdominal pain.

Coordinators will come out to the family's home on an evening that is convenient. Both the parent and child will fill out some questionnaires. Next, the parent and child will get instructions on how to fill out a diary to record any stomach pain the child is having and what their stools look like. The child will also collect a stool sample during the regular diet and diary collection period. Once the child has completed the diary, the child will go on a special diet for eight days to remove foods that may cause stomach pain (foods and drinks containing lactose, fructose, and sorbitol will be eliminated).

Two weeks later, the coordinators will come out to the family's home again to review the pain and stool diary that the child kept while on the special diet. The coordinators will explain how to collect some samples of urine, stool, and breath. These tests will evaluate the gastrointestinal (GI) tract for inflammation and transit time. If the special diet does not make the stomach pain go away, the child will be selected at random, like the flip of a coin, to be placed in one of two groups: one group that receives fiber or one group that receives a placebo or sugar pill. Fiber has been suggested to help children with stomach pain.

After the child has been on the treatment for 6 weeks, he/she will keep another diary and collect another set of samples of urine, stool, and breath.

The children will be followed at 3 months, 6 months and 18 months after the treatment period.

Children will be asked to collect additional stools

Study Design

Study Type:
Interventional
Actual Enrollment :
168 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Recurrent Abdominal Pain in Children
Study Start Date :
Jan 1, 2009
Actual Primary Completion Date :
Mar 1, 2014
Actual Study Completion Date :
Mar 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Fiber

Fiber added to diet for a total of 6 weeks.

Behavioral: Elimination Diet
Daily diet change for 8 days.

Placebo Comparator: Placebo

Placebo powder taken for a total of 6 weeks.

Behavioral: Elimination Diet
Daily diet change for 8 days.

Outcome Measures

Primary Outcome Measures

  1. Improvement in pain and stooling symptoms [The last two weeks of treatment and up to 18 months after treatment]

Secondary Outcome Measures

  1. Child anxiety, somatization, and coping [Four weeks prior to treatment and 6 months after treatment]

  2. Parental somatization, coping, and illness interaction [Four weeks prior to treatment and 6 months after treatment]

  3. Changes in GI Transit time [Prior to and after treatment]

  4. Changes in Breath Hydrogen production [Prior to and after treatment]

  5. Changes in GI Permeability [Prior to and after treatment]

  6. Changes in fecal calprotectin concentration [Prior to and after treatment]

Eligibility Criteria

Criteria

Ages Eligible for Study:
7 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children who have had at least one physician visit in the past year for abdominal pain or IBS symptoms.

  • Children with recurrent abdominal pain who meet the criteria for irritable bowel syndrome.

Exclusion Criteria:
  • Children who have another disease that accounts for stomach pain

  • Current use of anti-inflammatory medication

  • Children taking a GI medication that makes pain go away completely

  • Children with other chronic conditions including chronic pain conditions (e.g. heart condition, diabetes)

  • Children who have decreased growth

  • GI blood loss

  • Unexplained fever

  • Chronic severe diarrhea

  • Weight loss of > or = to 5% of body weight within 3 month prior to enrollment

  • History of abdominal surgeries

  • A history of suicide

  • Cognitive impairment significantly below average age and/or grade level

  • Non-English speaking parent or child

  • Vomiting >2x/month

  • Children currently in psychotherapy for abdominal pain.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Texas Children's Hospital Houston Texas United States 77030

Sponsors and Collaborators

  • Baylor College of Medicine
  • National Institute of Nursing Research (NINR)

Investigators

  • Principal Investigator: Robert Shulman, Baylor College of Medicine

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Robert Shulman, M.D., Professor of Pediatrics, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00526903
Other Study ID Numbers:
  • 17388
  • R01NR005337
First Posted:
Sep 10, 2007
Last Update Posted:
Mar 8, 2016
Last Verified:
Mar 1, 2016
Keywords provided by Robert Shulman, M.D., Professor of Pediatrics, Baylor College of Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2016